LV12208A - Hiv proteazes inhibitora pielietojums aids arstesanai - Google Patents

Hiv proteazes inhibitora pielietojums aids arstesanai

Info

Publication number
LV12208A
LV12208A LV980235A LV980235A LV12208A LV 12208 A LV12208 A LV 12208A LV 980235 A LV980235 A LV 980235A LV 980235 A LV980235 A LV 980235A LV 12208 A LV12208 A LV 12208A
Authority
LV
Latvia
Prior art keywords
opt
substd
aryl
halo
alkoxy
Prior art date
Application number
LV980235A
Other languages
English (en)
Other versions
LV12208B (lv
Inventor
Joseph P Vacca
Katherine M Holloway
Bruce D Dorsey
Randall W Hungate
James P Guare
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of LV12208A publication Critical patent/LV12208A/lv
Publication of LV12208B publication Critical patent/LV12208B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LVP-98-235A 1991-11-08 1998-10-26 Hiv proteāzes inhibitora pielietojums aids ārstēšanai LV12208B (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78950891A 1991-11-08 1991-11-08
US88382592A 1992-05-15 1992-05-15

Publications (2)

Publication Number Publication Date
LV12208A true LV12208A (lv) 1999-01-20
LV12208B LV12208B (lv) 1999-03-20

Family

ID=27120923

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-98-235A LV12208B (lv) 1991-11-08 1998-10-26 Hiv proteāzes inhibitora pielietojums aids ārstēšanai

Country Status (27)

Country Link
EP (1) EP0541168B1 (lv)
JP (1) JPH0733373B2 (lv)
KR (1) KR100273623B1 (lv)
AT (1) ATE163926T1 (lv)
AU (1) AU659234B2 (lv)
BG (1) BG61725B1 (lv)
CA (2) CA2081970C (lv)
CY (1) CY2090B1 (lv)
CZ (1) CZ287610B6 (lv)
DE (1) DE69224703T2 (lv)
DK (1) DK0541168T3 (lv)
ES (1) ES2112880T3 (lv)
FI (2) FI106025B (lv)
GR (1) GR3026334T3 (lv)
HK (1) HK1006060A1 (lv)
HU (1) HU220866B1 (lv)
IL (1) IL103613A (lv)
LV (1) LV12208B (lv)
NO (1) NO303383B1 (lv)
NZ (1) NZ244986A (lv)
PL (1) PL171340B1 (lv)
RO (1) RO115726B1 (lv)
RU (1) RU2131416C1 (lv)
SG (1) SG52731A1 (lv)
SK (1) SK281864B6 (lv)
UA (1) UA45945C2 (lv)
WO (1) WO1993009096A1 (lv)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
USH1649H (en) 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
RU2126794C1 (ru) 1992-03-11 1999-02-27 Нархекс Лимитед Аминопроизводные оксо- или гидроксизамещенных гидразинов, способ их получения и фармацевтические композиции для ингибирования ретровирусной протеазы
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
DE69333270T2 (de) 1992-03-11 2004-08-05 Narhex Ltd. Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ATE172717T1 (de) 1992-08-25 1998-11-15 Searle & Co Hydroxyethylaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
IL110255A (en) * 1993-07-16 1998-12-06 Merck & Co Inc Creation and resolution of 2 tert-butylcarboxamidopiprazine
US5463067A (en) * 1993-07-16 1995-10-31 Merck & Co., Inc. Process for making HIV protease inhibitors
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
US5455351A (en) * 1993-12-13 1995-10-03 Abbott Laboratories Retroviral protease inhibiting piperazine compounds
CZ288312B6 (en) * 1993-12-15 2001-05-16 Merck & Co Inc HIV-protease inhibitors and pharmaceutical preparations in which they are comprised
US5428167A (en) * 1994-01-14 1995-06-27 American Cyanamid Company Asymmetric synthesis of intermediates for retroviral protease inhibitor compounds
US5733882A (en) * 1994-01-17 1998-03-31 Smithkline Beecham Corporation Retroviral protease inhibitors
TW472047B (en) * 1994-02-04 2002-01-11 Merck & Co Inc Process for making HIV protease inhibitors
TW380137B (en) * 1994-03-04 2000-01-21 Merck & Co Inc Process for making an epoxide
US5728840A (en) * 1994-03-04 1998-03-17 Merck & Co., Inc. Process for making an epoxide
US6127372A (en) * 1994-03-07 2000-10-03 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US5420353A (en) * 1994-03-11 1995-05-30 Merck & Co., Inc. Regiospecific process to make cis-1-amino-2-alkanol from epoxide
US5449830A (en) * 1994-03-11 1995-09-12 Marck & Co., Inc. Regiospecific processes to make CIS-1-Amino-2-Alkanol from Diol or Halohydrin
EP0756593B1 (de) * 1994-04-20 2000-09-20 Lonza Ag Verfahren zur herstellung von 2-piperazincarbonsäurederivaten
KR100389151B1 (ko) * 1994-04-22 2003-10-04 고에이 가가쿠 고교 가부시키가이샤 광학활성N-tert-부틸-2-피페라진카르복시아미드의제조방법및그라세미화법
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US5476874A (en) * 1994-06-22 1995-12-19 Merck & Co., Inc. New HIV protease inhibitors
IL114808A (en) * 1994-08-11 1999-10-28 Merck & Co Inc Combinations of protease inhibitors for the treatment of hiv infection and aids
GB2292146A (en) * 1994-08-11 1996-02-14 Merck & Co Inc HIV protease inhibitors useful for the treatment of AIDS
US5612217A (en) * 1994-10-25 1997-03-18 Merck & Co., Inc. Streptomyces sp. MA 7074 (ATCC 55605) used for microbial synthesis of HIV protease inhibitors
EP0785786A4 (en) * 1994-10-25 1998-01-28 Merck & Co Inc MICROBIAL SYNTHESIS OF HIV PROTEASE INHIBITORS
DE4446025A1 (de) * 1994-12-22 1996-06-27 Basf Ag 2-Caroxamido-1,4,5,6-tetrahydropyrazine
ES2181865T3 (es) * 1995-01-23 2003-03-01 Lonza Ag Procedimiento para preparar amidas de acido 1,4,5,6, tetrahidro-pirazina-2-carboxilico.
US5618937A (en) * 1995-03-15 1997-04-08 Merck & Co., Inc. Process to make HIV protease inhibitor from (2S)-4-picolyl-2-piperazine-t-butylcarboxamide
US5508404A (en) * 1995-03-15 1996-04-16 Merck & Co., Inc. Reductive amination process
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5612484A (en) * 1995-05-18 1997-03-18 Merck & Co., Inc. Process for making HIV protease inhibitors
US5605819A (en) * 1995-05-19 1997-02-25 Merck & Co., Inc. Quantitative conversion of indene to (1S,2R) indene oxide and (1S,2R)-indandiol by combination of haloperoxidase bioconversion and chemical steps
DE59608234D1 (de) * 1995-05-23 2002-01-03 Lonza Ag Verfahren zur Herstellung von optisch aktiven 2-Piperazincarbonsäurederivaten
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
ES2246498T3 (es) 1995-11-13 2006-02-16 Vitaleech Bioscience N.V. Aislados antivirales obtenidos de sanguijuelas.
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
CA2201218C (en) * 1996-04-23 2004-09-28 Rudolf Fuchs Process for the preparation of optically active piperazine-2-carboxylic acid derivatives
DE19620494A1 (de) * 1996-05-21 1997-11-27 Basf Ag 1-(Halogenalkanoyl)-2-carboxamido-1,4,5,6-tetrahydropyrazine
US5747540A (en) * 1996-10-21 1998-05-05 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6645961B1 (en) 1997-03-07 2003-11-11 Merck & Co., Inc. Dry granulation formulation for an HIV protease inhibitor
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6251906B1 (en) 1998-05-15 2001-06-26 Abbott Laboratories Retroviral protease inhibiting compounds
EP1077977A1 (en) * 1998-05-15 2001-02-28 Abbott Laboratories Retroviral protease inhibiting compounds
PT1086076E (pt) 1998-06-19 2005-05-31 Vertex Pharma Inibidores de sulfonamida de aspartil protease
AU4862799A (en) 1998-07-08 2000-02-01 G.D. Searle & Co. Retroviral protease inhibitors
EP1155009A2 (en) * 1999-02-19 2001-11-21 Oklahoma Medical Research Foundation Protease inhibitors that overcome drug resistance
WO2001038332A1 (en) 1999-11-24 2001-05-31 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors
CN100536833C (zh) * 2000-01-19 2009-09-09 艾博特公司 改良药物配方
JP2005508940A (ja) * 2001-10-05 2005-04-07 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用なアリルアミド
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US7037913B2 (en) * 2002-05-01 2006-05-02 Bristol-Myers Squibb Company Bicyclo 4.4.0 antiviral derivatives
MX2009009850A (es) 2007-03-12 2009-09-24 Nektar Therapeutics Conjugados de inhibidor de oligomero-proteasa.
EP2262538B1 (en) 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
WO2016065248A1 (en) 2014-10-23 2016-04-28 Complete Genomics, Inc. Signal confinement sequencing (scs) and nucleotide analogues for signal confinement sequencing
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids

Also Published As

Publication number Publication date
HU220866B1 (en) 2002-06-29
ES2112880T3 (es) 1998-04-16
ATE163926T1 (de) 1998-03-15
AU659234B2 (en) 1995-05-11
AU2819992A (en) 1993-05-13
CA2195027C (en) 2000-01-11
DE69224703T2 (de) 1998-10-15
FI981591A (fi) 1998-07-10
LV12208B (lv) 1999-03-20
DK0541168T3 (da) 1998-05-11
CA2081970A1 (en) 1993-05-09
RO115726B1 (ro) 2000-05-30
RU2131416C1 (ru) 1999-06-10
CY2090B1 (en) 2002-04-05
JPH05279337A (ja) 1993-10-26
HK1006060A1 (en) 2003-07-10
SK281864B6 (sk) 2001-08-06
DE69224703D1 (de) 1998-04-16
NO941696L (lv) 1994-06-24
SK52394A3 (en) 1995-02-08
NZ244986A (en) 1995-10-26
CZ287610B6 (cs) 2001-01-17
IL103613A (en) 1999-05-09
PL171340B1 (pl) 1997-04-30
JPH0733373B2 (ja) 1995-04-12
KR100273623B1 (ko) 2000-12-15
CZ111094A3 (en) 1995-03-15
EP0541168B1 (en) 1998-03-11
FI981591A0 (fi) 1992-11-03
CA2195027A1 (en) 1993-05-09
NO303383B1 (no) 1998-07-06
HUT70519A (en) 1995-10-30
NO941696D0 (no) 1994-05-06
WO1993009096A1 (en) 1993-05-13
FI942112A (fi) 1994-05-06
UA45945C2 (uk) 2002-05-15
SG52731A1 (en) 1998-09-28
BG98745A (bg) 1995-03-31
GR3026334T3 (en) 1998-06-30
EP0541168A1 (en) 1993-05-12
CA2081970C (en) 1997-07-08
FI106025B (fi) 2000-11-15
HU9401424D0 (en) 1994-08-29
FI942112A0 (fi) 1994-05-06
BG61725B1 (bg) 1998-04-30
IL103613A0 (en) 1993-04-04

Similar Documents

Publication Publication Date Title
LV12208A (lv) Hiv proteazes inhibitora pielietojums aids arstesanai
DE3684415D1 (de) Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel.
ATE204269T1 (de) Substituierte biphenyl- oder phenylpyridinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
AR079541A1 (es) Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms
ATE237596T1 (de) Chinazolinderivate und deren verwendung als vegf hemmer
NO933452D0 (no) Et terapeutisk middel for parkinson's sykdom
HUP0204474A2 (hu) 1H-imidazopiridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MY129540A (en) Quinazoline derivatives, pharmaceutical compositions containing them processes for their preparation and their use in the production of an antiangiogenic and/or vascular permeability reducing effect
ATE210134T1 (de) Heterocyclisch substituierte imidazolidine, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen
BG98740A (en) Substituted pyrazolylpyrazoles, methods for their preparation, preparation of intermediate products and the usage of the compounds as herbicides
KR900700467A (ko) 마크로시클릭 킬레이트 제 및 이들의 킬레이트
CO5540322A2 (es) Nuevos derivados heterociclicos que comprenden un anillo de tetrahidroisoquinolina y uso farmaceutico de los mismos
YU141690A (sh) Aromatični amidi ugljene kiseline
ES2142320T3 (es) Derivados de 2-pirazinil-etilamina y su uso como productos farmaceuticos.
ES367846A1 (es) Procedimiento para la produccion de compuestos de pirazolo-diazepinona.
ES8101045A1 (es) Procedimiento para la preparacion de derivados de acidos pi-rrolidinilsulfamoilbenzoicos sustituidos
DE2963724D1 (en) Clavulanic acid derivatives, their preparation and pharmaceutical compositions containing them
TH58670B (th) อนุพันธ์ 2-อะมิโน-3-(แอลคิล)-พิริมิโดน